{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T04:17:31Z","timestamp":1773634651356,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jiac.2025.102834","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:02:03Z","timestamp":1760803323000},"page":"102834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir\/emtricitabine\/tenofovir alafenamide in the Phase 3b randomized SOLAR study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-873X","authenticated-orcid":false,"given":"Eisuke","family":"Adachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yokomaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-2167","authenticated-orcid":false,"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Shirasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Sutherland-Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Murungi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102834_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/dyv352","article-title":"The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11","volume":"45","author":"Lesko","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2025.102834_bib2","article-title":"1329. Experiences and emotional challenges of antiretroviral treatment (ART)\u2014Findings from the positive perspectives study","volume":"6","author":"De Los Rios","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102834_bib4","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","year":"2024"},{"key":"10.1016\/j.jiac.2025.102834_bib5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jama.2024.2985","article-title":"Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel","volume":"331","author":"Sax","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102834_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10461-024-04490-0","article-title":"Improvements in patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir\/emtricitabine\/tenofovir alafenamide in the phase 3b SOLAR study","volume":"29","author":"Mussini","year":"2024","journal-title":"AIDS Behav"},{"key":"10.1016\/j.jiac.2025.102834_bib7","series-title":"Poster presented at the 25th International AIDS Conference; Munich, Germany","article-title":"12-month outcomes of cabotegravir plus rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and patient-reported outcomes from people with HIV-1 in the German CARLOS study","author":"Jonsson-Oldenb\u00fcttel","year":"2024"},{"key":"10.1016\/j.jiac.2025.102834_bib8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2025.102834_bib9","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2025.102834_bib10","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102834_bib11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2025.102834_bib12","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102834_bib13","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102834_bib14","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2025.102834_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1745-6215-13-138","article-title":"Drug safety assessment in clinical trials: methodological challenges and opportunities","volume":"13","author":"Singh","year":"2012","journal-title":"Trials"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T03:05:32Z","timestamp":1773630332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1341321X25002314"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102834","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir\/emtricitabine\/tenofovir alafenamide in the Phase 3b randomized SOLAR study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102834"}}